Premium
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
Author(s) -
Omura George,
Blessing John A.,
Ehrlich Clarence E.,
Miller Alexander,
Yordan Edgardo,
Creasman William T.,
Homesley Howard D.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j
Subject(s) - medicine , gynecologic oncology , oncology , cisplatin , cyclophosphamide , doxorubicin , randomized controlled trial , ovarian carcinoma , chemotherapy , ovarian cancer , cancer
A randomized clinical trial was conducted in women with bulky (suboptimal) Stage III and Stage IV ovarian carcinoma, using doxorubicin (Adriamycin) and cyclophosphamide with or without cisplatin. There were 440 evaluable cases, of which 227 had measurable disease. One hundred twenty of these latter patients were treated with cyclophosphamide and doxorubicin (CA), while 107 received cyclophosphamide, doxorubicin and cisplatin (CAP). The clinical complete response (CR) rate for CA was 26% (31/120) compared with 51% (55/107) for CAP ( P = <0.0001). Of 23 CRs receiving CA who had a second‐look laparotomy, only four were negative; of 39 CRs receiving CAP and a second‐look, 13 were negative (not statistically significant). The response duration for patients with measurable disease (median 14.6 versus 8.8 months), progression‐free interval for all patients (13.1 versus 7.7 months), and survival for patients with measurable disease (19.7 versus 15.7 months) showed a statistically significant advantage for CAP; however, there was no difference in survival of patients with nonmeasurable disease. Toxicity was more severe with CAP but was tolerable. Thus, the addition of cisplatin improves the chemotherapy of advanced ovarian carcinoma.